A prospective, single-arm, phase 2 trial exploring the use of pamiparib combined with surufatinib as neoadjuvant therapy for advanced, unresectable ovarian cancer (PASSION).
Authors: Bairong Xia, Wenju Peng, Yao Chen, Wulin Shan, Wenjing Jiang, Wei Xiong
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.5589
Source:
Full article
Abstract
5589